coronaviru ding guidanc lower pt
viewray result line pre-releas guid howev
wider expect compani detail potenti coronavirus-rel
impact current introduc uncertainti outlook ou activ
impact travel restrict us activ impact hospit limit
visitor sale discuss delay note one last
compani report sinc compani alreadi thick coronaviru
storm seem prudent temper outlook continu believ mrgrt futur
rad onc despit near-term coronaviru hiccup said would
remiss highlight disappoint execut pre-coronaviru
introduc estim pt get tweak accordingli
coronaviru impact current nine mridian instal impactedseven
asia two italydu travel restrict one system expect
recogn revenu expect slip confer cancel
client limit site visit impact sale discuss order cancel
far us instal move ahead far
result rev vs estim pre-
announc three revenu unit one upgrad four unit order total
receiv backlog two system remov
math right compani ad unit order
backlog cancel last two year
result far left quarter recogn
rev far one system expect ship coronavirus-affect
area month could delay receiv two unit order date
guid introduc see rev vs
estim consensu end guid assum eight instal two
upgrad high-end assum expect cash burn
delta guid partli reflect uncertainti around nine instal region
coronaviru travel restrict seven asia two itali estim get
uptick patient treat compani announc patient
treat far system system updat
impli signific uptick machin util potenti good sign
mrgrt compani work elekta secur non-apm medicar
patient higher reimburs ou territori japan
year price histori viewray
manufactur market
analyst certif import disclosur see disclosur
convent radiat therapi drive dark
mr-guid radiat therapi see drive
see tumor deliv radiat deliv
higher dose properli target tumor theoret
outcom better
new reimburs model could caus uptick mr-linac
could garner strateg interest bodi clinic
evid build
continu hold price point
current reimburs model remain place
decis bundl
bundl payment model final realiti
elekta uniti real-tim gate on-tabl adapt delay
time-frame
varian start joint bid
lower price compet elekta
market mr-guid linac slow bundl pay
new immunotherapi develop challeng radiat
therapi cost basi
pt deriv use multipl sale estim slight discount aggreg
med-tech univers view paradigm shift radiat oncolog space mr-guid rt system provid first
time abil visual tumor real-tim radiat deliveri deliv higher dose control manner improv outcom
reduc side effectsal cost-effect way
far execut risk main risk stori
battl domin mr-guid linac space battl elekta intens elekta abl compet
global footprint relationship hospit financi wherewith rel novic space henc
compet gorilla bring set risk
radiat oncolog market larg extent depend country-specif geopolit event healthcar expenditure-driven
event variou countri cancer incid continu rise unab sudden slowdown capit spend neg
effect stori
note view stock trade specul appropri risk-toler investor
statement oper
good sold
